Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17663311 | 0.83 | ALDH1A1 (0.54) | ALDH1A1LMNAEGFRKDM4EHPGD | |
| SCHEMBL10553462 | 0.81 | KDM4E (0.59) | ALDH1A1LMNAEGFRKDM4EHPGD | |
| SCHEMBL29011088 | 0.80 | RAB9A (0.63) | ALDH1A1EGFRKDM4EHPGDNPC1 | |
| SCHEMBL26777806 | 0.80 | ALDH1A1 (0.51) | ALDH1A1EGFRKDM4EHPGDPKM | |
| SCHEMBL9923084 | 0.79 | EGFR (0.50) | ALDH1A1EGFRKDM4EHPGDPKM | |
| SCHEMBL17659943 | 0.79 | NPC1 (0.55) | ALDH1A1EGFRKDM4EHPGDPKM | |
| SCHEMBL28876889 | 0.78 | EGFR (0.49) | ALDH1A1EGFRKDM4EHPGDPKM | |
| SCHEMBL18647956 | 0.76 | EGFR (0.51) | ALDH1A1EGFRKDM4EHPGDPKM | |
| SCHEMBL485159 | 0.74 | ALDH1A1 (1.00) | ALDH1A1LMNAKDM4EHPGDNPC1 | |
| SCHEMBL25374503 | 0.73 | KDM4E (0.50) | ALDH1A1LMNAEGFRKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097594-B2 | Macrolides and ketolides having antimicrobial activity | WOCKHARDT LTD. (IN) | 2012-01-17 | — | — | US | disclosed |
| US-20090247478-A1 | Novel macrolides and ketolides having antimicrobial activity | SINDKHEDKAR MILIND DATTATRAYA | 2009-10-01 | — | — | US | disclosed |
| EP-2056844-A2 | NOVEL MACROLIDES AND KETOLIDES HAVING ANTIMICROBIAL ACTIVITY | Wockhardt Research Centre (IN) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008023248-A2 | NOVEL MACROLIDES AND KETOLIDES HAVING ANTIMICROBIAL ACTIVITY | WOCKHARDT RESEARCH CENTRE (IN) | 2008-02-28 | — | — | WO | disclosed |
| EP-0222576-B1 | HETEROCYCLIC OXOPHTHALAZINYL ACETIC ACIDS | PFIZER INC. (US) | 1992-03-18 | — | — | EP | disclosed |
| US-4939140-A | ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1990-07-03 | — | — | US | disclosed |
| EP-0222576-A2 | Heterocyclic oxophthalazinyl acetic acids | PFIZER INC. (US) | 1987-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247478-A1 | Novel macrolides and ketolides having antimicrobial activity | CYP51A1, CASP12, LSS | ALDH1A1 4164/4885LMNA 2135/4885EGFR 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.